MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. UNH
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

UnitedHealth Group Incorporated (UNH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

UnitedHealth Group Incorporated
NYSE•Healthcare•Healthcare Plans
$375.21-0.05(<0.01%)After hours
Market Cap
$338.44B
P/E
24.0x
P/S
0.8x
P/B
3.2x

UnitedHealth Group Incorporated operates as a health care company in the United States and internationally. It operates through four segments: Optum Health, Optum Insight, Optum Rx; and UnitedHealthcare. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services with patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, public entities, life sciences companies and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease and drug therapy management. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; Medicaid plans, including Temporary Assistance to Needy Families; Children's Health Insurance Programs; Dual SNPs; Long-Term Services and Supports; Aged, Blind and Disabled; and other federal, state, and community health care programs. and health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. UnitedHealth Group Incorporated was founded in 1974 and is based in Eden Prairie, Minnesota.

C

How this company scores

AverageMetricSide Score: 53/100

Strongest: Cash & Earnings Quality (18/25); weakest: Profitability (8/25).

Profitability8/25
Growth13/25
Balance Sheet & Red Flags14/25
Cash & Earnings Quality18/25
Strengths
Cash-backed earningsConsistent free cash flowConsistent growthNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 24.0x5y range 13.3x – 37.7x
P/E 24.0x · near its 20-quarter median

Currently near its 20-quarter median.

P/S · 0.8x5y range 0.5x – 1.6x
P/S 0.8x · below its 20-quarter median

Currently below its 20-quarter median.

P/B · 3.2x5y range 2.3x – 6.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 34.0% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Price & Volume
Market Cap $338.44B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$450.13B
7Q
Q. Revenue
$112.03B
0%
TTM EBITDA
$25.96B
26%
TTM Op. Income
$21.68B
30%
Q. Op. Income
$7.99B
55%
TTM Net Income
$14.12B
34%
Q. Net Income
$5.48B
61%
EPS
$6.06
61%
Shares Out.
$902.00M
1%
$450.13B in TTM revenue grew 6.5% YoY, reaching $112.03B last quarter. TTM EBITDA of $25.96B and TTM operating income of $21.68B show growth is flowing through to the bottom line. TTM net income of $14.12B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
88.1%
3Q
EBITDA Margin
8.1%
44%
Op. Margin
7.1%
55%
Net Margin
4.9%
60%
Op. margin of 7.1% is up 2.5% YoY — cost efficiency is improving. Net margin at 4.9% and gross margin of 88.1% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 55% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
24.0x
80%
P/S Ratio
0.8x
12%
P/B Ratio
3.2x
15%
At 24.0x P/E, the stock trades within typical market levels. P/S of 0.8x and P/B of 3.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 80% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$309.73B
0%
Cash
$28.59B
2Q
Long-Term Debt
$69.50B
4Q
Book Value
$104.51B
2Q
D/E Ratio
0.7
2Q
Debt/EBITDA
7.7
35%
With $309.73B in assets and $69.50B in long-term debt, D/E is 0.7and book value is $104.51B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$11.05B
2Q
TTM Free Cash Flow
$23.62B
2Q
FCF Margin
5.2%
2Q
FCF / Net Income
1.7
3Q
TTM FCF of $23.62B on $11.05B in operating cash flow. The FCF / Net Income ratio of 1.7x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
ISRG$187.84B
Intuitive Surgical
Medical Instruments & Supplies
P/B 3.2x
· below its 20-quarter median

Currently below its 20-quarter median.